News
- Author:
- Miriam E. Tucker
Publish date: March 2, 2023
As of May 1, nonbranded insulins will cost $25 a vial, and Lilly says it will immediately cap out-of-pocket costs at $35 per month.
News
- Author:
- Miriam E. Tucker
Publish date: February 28, 2023
In randomized trial, the old cardiac agent slowed the destruction of insulin-producing beta cells in youth with new-onset type 1 diabetes.
News
- Author:
- Miriam E. Tucker
Publish date: February 23, 2023
Real-time continuous glucose monitoring and insulin pump use yielded more time in target glucose range vs. intermittently scanned CGM and injection...
News
- Author:
- Miriam E. Tucker
Publish date: February 15, 2023
Several studies conducted early in the pandemic suggested increased risks for both new-onset diabetes and cardiometabolic diseases&n...
News
- Author:
- Miriam E. Tucker
Publish date: February 14, 2023
The prevalence of overweight/obesity was similar for people with type 1 diabetes and those without diabetes in a nationwide survey.
News
- Author:
- Miriam E. Tucker
Publish date: January 26, 2023
Meta-analysis finds small increased risk of retinopathy worsening after starting injectable semaglutide.
News
- Author:
- Miriam E. Tucker
Publish date: January 26, 2023
Prescription-only device works with compatible continuous glucose monitors and insulin pumps for people with type 1 diabetes aged 6 years or older....
News
- Author:
- Miriam E. Tucker
Publish date: January 23, 2023
Another SGLT2 inhibitor has been approved for type 2 diabetes based on results from 23 clinical trials in 5,000 patients.
News
- Author:
- Miriam E. Tucker
Publish date: January 17, 2023
Findings suggest that at time of type 2 diabetes diagnosis some might not benefit from metformin as first-line treatment. Dual or other therapy may...
News
- Author:
- Miriam E. Tucker
Publish date: January 13, 2023
Top-line results from the phase 3 trial of ORMD-0801 show that the oral insulin product didn’t meet the trial’s endpoint for change from baseline h...
News
- Author:
- Miriam E. Tucker
Publish date: January 6, 2023
Beneficiaries who take insulin via pen or syringe, covered under Medicare part D, fall under the $35/month co-pay cap.
News
- Author:
- Miriam E. Tucker
Publish date: December 20, 2022
There have been major increases in prediabetes in the United States and globally over the past 2 decades.
News
- Author:
- Miriam E. Tucker
Publish date: December 13, 2022
The new 2023 American Diabetes Association Standards of Care address management of diabetes and its complications, as well as social determinants o...
News
- Author:
- Miriam E. Tucker
Publish date: December 12, 2022
The new version has several advantages over the G6, including smaller size, shorter warm-up time, and a 12-hour grace period before expiring.
News
- Author:
- Miriam E. Tucker
Publish date: December 1, 2022
The FDA approval of teplizumab for the delay of type 1 diabetes highlights the need to cost effectively identify those at risk who could potentiall...
